Answer
Yes, glofitamab (Columvi) can cause cytokine release syndrome, including severe reactions, and must be administered under experienced healthcare supervision with access to appropriate medical support.
Sources for this answer
- Columvi 2.5 mg, 10 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.2 Posology and method of administration · Version 6Document updated
Sources checked